Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Study of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

NCT05053880 is registered in ClinicalTrials.gov with Accendatech USA Inc. as lead sponsor.

NCT NCT05053880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05053880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Study of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Lead sponsor
Accendatech USA Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 22, 2021
Completion date
December 31, 2026
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma multiforme(gbm)